Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients.

@article{Lee2009LongerDO,
  title={Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients.},
  author={T J F Lee and Marina N{\'u}{\~n}ez},
  journal={HIV clinical trials},
  year={2009},
  volume={10 3},
  pages={153-9}
}
BACKGROUND HBV-HIV co-infection is associated with increased liver-related morbidity and mortality. Herein we analyzed HBV-related virologic and clinical outcomes in HBV-HIV patients in the HAART era. METHODS HBsAg positive HIV-infected patients followed at a US academic center between 1990 and 2008 were assessed in a retrospective and longitudinal study. Factors associated with HBsAg and/or HBeAg clearance and with advanced liver disease were evaluated using logistic regression. RESULTS 72… CONTINUE READING